Last reviewed · How we verify
OMTRYG (OMEGA-3-ACID ETHYL ESTERS TYPE A)
OMTRYG (generic name: OMEGA-3-ACID ETHYL ESTERS TYPE A) is a drug developed by OSMOTICA PHARM US. It is currently FDA-approved.
At a glance
| Generic name | OMEGA-3-ACID ETHYL ESTERS TYPE A |
|---|---|
| Sponsor | OSMOTICA PHARM US |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
- Taste perversion
- Eructation
- Dyspepsia
- Constipation
- Gastrointestinal disorder
- Vomiting
- Increased ALT
- Increased AST
- Pruritus
- Rash
Serious adverse events
- Anaphylactic reaction
- Hemorrhagic diathesis
Key clinical trials
- A Two-part, Open-label, Randomised, Crossover, Multicentre, Phase II Study to Investigate the Presence of Pancreatic Exocrine Insufficiency (PEI) in Patients With Type 2 Diabetes Mellitus, and to Inve (Phase 2)
- Effects of Treatment With Omacor for 6 Weeks on Preprandial and Postprandial Endothelial Function Following a High Fat Meal in Patients With Type 2 Diabetes Mellitus (Phase 4)
- A Multicenter, International Randomized, 2x2 Factorial Design Study to Evaluate the Effects of Lantus (Insulin Glargine) Versus Standard Care, and of Omega-3 Fatty Acids Versus Placebo, in Reducing Ca (Phase 3)
- A Study of Cardiovascular Events iN Diabetes - A Randomized 2x2 Factorial Study of Aspirin Versus Placebo, and of Omega-3 Fatty Acid Supplementation Versus Placebo, for Primary Prevention of Cardiovas (Phase 4)
- An Open-label, Single and Repeat Single Ascending Dose Escalation Study to Compare the Pharmacokinetics of Metformin Eicosapentaenoate With Metformin Hydrochloride and Icosapent Ethyl Following Oral A (Phase 1)
- A Multicenter, Randomized, Active Comparator, Placebo Controlled, Double-blind Pilot Study to Assess the Efficacy and Safety of LCQ908 Alone and in Combination With Fenofibrate or Lovaza® in Patients (Phase 2)
- The Role of Lovaza® on Microvascular Function and Lipoprotein Profile in Type 2 Diabetes (Phase 4)
- Efficacy and Safety of Co-administration of Omacor Plus Atorvastatin Compared With Atorvastatin Monotherapy in Patients With Type Ⅱb Dyslipidemia: a Multicenter, Double-blind, Randomized, Active-contr (Phase 3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OMTRYG CI brief — competitive landscape report
- OMTRYG updates RSS · CI watch RSS
- OSMOTICA PHARM US portfolio CI
Frequently asked questions about OMTRYG
What is OMTRYG?
OMTRYG (OMEGA-3-ACID ETHYL ESTERS TYPE A) is a pharmaceutical drug developed by OSMOTICA PHARM US.
Who makes OMTRYG?
OMTRYG is developed and marketed by OSMOTICA PHARM US (see full OSMOTICA PHARM US pipeline at /company/osmotica-pharm-us).
What is the generic name of OMTRYG?
OMEGA-3-ACID ETHYL ESTERS TYPE A is the generic (nonproprietary) name of OMTRYG.
What development phase is OMTRYG in?
OMTRYG is FDA-approved (marketed).
What are the side effects of OMTRYG?
Common side effects of OMTRYG include Taste perversion, Eructation, Dyspepsia, Constipation, Gastrointestinal disorder, Vomiting. Serious adverse events: Anaphylactic reaction, Hemorrhagic diathesis.
Related
- Manufacturer: OSMOTICA PHARM US — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing